Pediatric MATCH: Trk Inhibitor LOXO-101 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions
Complete Title: APEC1621 NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)- PHASE 2 SUBPROTOCOL OF LOXO-101 (LAROTRECTINIB) IN PATIENTS WITH TUMORS HARBORING ACTIONABLE NTRK FUSIONS
Trial Phase: II
Investigator: Navin Pinto
This phase II trial studies Trk inhibitor LOXO-101 in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with NTRK fusions that have spread to other places in the body and have come back or do not respond to treatment. Trk inhibitor LOXO-101 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Central Nervous System (CNS)
Pediatric Cancers, Miscellaneous
Lymphoma, Non-Hodgkin (NHL)
Neuroectodermal Tumors, Primitive (PNET)
Neoplasms, Germ Cell and Embryonal
Neoplasms, Connective and Soft Tissue
Immune System Diseases
Nervous System Diseases
Neuroectodermal Tumors, Primitive, Peripheral
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
APEC1621 NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)- PHASE 2 SUBPROTOCOL OF LOXO-101 (LAROTRECTINIB) IN PATIENTS WITH TUMORS HARBORING ACTIONABLE NTRK FUSIONS